OUTCOMES OF THE LONG-TERM ADMINISTRATION OF MACROLIDE ANTIBIOTICS IN CHILDREN WITH BRONCHIECTASES: FREQUENTLY ASKED QUESTIONS
https://doi.org/10.15690/vsp.v17i2.1884
Abstract
The article discusses issues related to the long-term administration of macrolide antibiotics for a bronchoectatic disorder of the pulmonary system in children. The relevant information about the results of long-term intake of macrolides in adults and children, the effective dose titration, possible toxic effects of therapy, including the development of cardiotoxic effect and ways to prevent it, has been enlightened in detail. It has been noted that a limited number of clinical studies involving children determine the need for studying the possibility to extrapolate adult treatment.
About the Authors
Natal’ya B. Lazareva
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest:
Russian Federation
Disclosure of interest:
Not declared
Evgeniya V. Chikh
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest:
Russian Federation
Disclosure of interest:
Not declared
Ekaterina V. Rebrova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest:
Russian Federation
Disclosure of interest:
Not declared
References
1. Inghammar M, Nibell O, Pasternak B, et al. Long-term risk of cardiovascular death with use of clarithromycin and roxithromycin: a nationwide cohort study. Am J Epidemiol. 2018;187(4):777–785. doi: 10.1093/aje/kwx359.
2. Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018;(3): CD012406. doi: 10.1002/14651858.CD012406.pub2.
3. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187(10):1118–1126. doi: 10.1164/rccm.201210-1937OC.
4. Edwards EA, Twiss J, Byrnes CA. Treatment of paediatric noncystic fibrosis bronchiectasis. Expert Opin Pharmacother. 2004;5(7): 1471–1484. doi: 10.1517/14656566.5.7.1471.
5. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369(9560): 482–490. doi: 10.1016/S0140-6736(07)60235-9.
6. van der Gast CJ, Cuthbertson L, Rogers GB, et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc. 2014;11(7):1039–1048. doi: 10.1513/AnnalsATS.201312-456OC.
7. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med. 2013;1(3):262–274. doi: 10.1016/S22132600(13)70038-9.
8. Kapur N, Masters IB, Chang AB. Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations. Respir Med. 2009;103(11):1681–1687. doi: 10.1016/j.rmed.2009.05.007.
9. Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung d isease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust. 2015;202(3):130.
10. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust. 2010;193(6):356–365. doi: 10.5694/mja14.00287.
11. Osnovy dokazatel’noy meditsiny. Uchebnoe posobie. Ed by R.G. Oganov. Moscow: Silitseya-Poligraf; 2010. 136 p. (In Russ).
12. Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(8):610–620. doi: 10.1016/S22132600(13)70185-1.
13. Bilton D. Azithromycin in bronchiectasis: evidence in children? Lancet Respir Med. 2013;1(8):587–589. doi: 10.1016/S22132600(13)70195-4.
14. Hnin K, Nguyen C, Carson KV, et al. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst Rev. 2015;(8):CD001392. doi: 10.1002/14651858.CD001392.pub3.
15. Koh YY, Lee MH, Sun YH, et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J. 1997;10(5):994–999. doi: 10.1183/09031936.97.10050994.
16. Redding GJ, Singleton RJ, Valery PC, et al. Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Chest. 2014;146(3):762–774. doi: 10.1378/chest.14-0126.
17. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics — part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration. 2011;81(1):75–87. doi: 10.1159/000320320.
18. Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med. 2008;102(10):1494–1496. doi: 10.1016/j.rmed.2008.06.005.
19. Tsoy AN, Lazareva NB, Berdnikova NG. Ambul atornaya terapiya infektsii nizhnikh dykhatel’nykh putei. Preimu shchestva makrolidov. Spravochnik poliklinicheskogo vracha. 2008;(14–15):4–8. (In Russ).
20. Chernysheva OE, Soroka YuA. Makrolidy v lechenii infektsiy organov dykhaniya u detey. Na dopomogu pediatru. 2011;(1):37–42. (In Russ).
21. Yalcin E, Kiper N, Ozcelik U, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006;31(1):49–55. doi: 10.1111/j.1365-2710.2006.00708.x.
22. Altenburg J1, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–1259. doi: 10.1001/jama.2013.1937.
23. Caron F, Bouaniche M, Delatour F, et al. Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings. Antimicrob Agents Chemother. 1996; 40(8):1796–1800.
24. Pomares X, Monton C, Espasa M, et al. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis. 2011;6:449–456. doi: 10.2147/COPD.S23655.
25. Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65(9):631–640.
26. Sinopal’nikov AI, Andreeva IV, Stetsuyk OU. The safety of macrolide antibiotics: critical analysis. Klin Med (Mosk). 2012;90(3):23–30. (In Russ).
27. Simko J, Csilek A, Karaszi J, Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection. 2008;36(3):194–206. doi: 10.1007/s15010-007-7211-8.
28. Inghammar M, Nibell O, Pasternak B, et al. Long-term risk of cardiovascular death with use of clarithromycin and roxithromycin: a nationwide cohort study. Am J Epidemiol. 2018;187(4):777–785. doi: 10.1093/aje/kwx359.
29. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187(10):1118–1126. doi: 10.1164/rccm.201210-1937OC.
30. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369(9560): 482–490. doi: 10.1016/S0140-6736(07)60235-9.
31. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med. 2013;1(3):262–274. doi: 10.1016/S22132600(13)70038-9.
32. Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung d isease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust. 2015;202(3):130.
Review
For citations:
Lazareva N.B., Chikh E.V., Rebrova E.V. OUTCOMES OF THE LONG-TERM ADMINISTRATION OF MACROLIDE ANTIBIOTICS IN CHILDREN WITH BRONCHIECTASES: FREQUENTLY ASKED QUESTIONS. Current Pediatrics. 2018;17(2):166-169. (In Russ.) https://doi.org/10.15690/vsp.v17i2.1884
Views:
1009
Email this article 
